U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07290569) titled 'Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis' on Dec. 16.
Brief Summary: This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Study Start Date: Dec. 03
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis
Intervention:
DRUG: ORKA-001
ORKA-001 administered by subcutaneous (SC) injection
OTHER: Placebo
Placebo administered by subcutaneous (SC) injection
Recruitment Status: RECRUITING
Sponsor: Oruka Therapeutics, Inc.
Published by ...